Kestra Medical Technologies Ltd

Kestra Medical Technologies Ltd(KMTS)股票分析

$27.240

-1.367 (-5.02%)收盤時

Loading chart…
最高
29.010
開盤
28.710
成交量加權均價
27.75
成交量
521.92K
市值
—
最低
26.990
成交金額
14.48M
企業價值/稅息折舊攤銷前利潤(TTM)
-7.50

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.

AI 分析 of Kestra Medical Technologies Ltd (KMTS)

買進

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

估值指標

Kestra Medical Technologies Ltd(KMTS)目前預期本益比為 0.00,5 年平均預期本益比為 -9.68。

預期本益比

嚴重高估
5 年均值 P/E
-9.68
目前P/E
0.00
高估
-6.54
低估
-12.82

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-10.35
目前EV/EBITDA
-7.50
高估
-4.05
低估
-16.65

預期股價營收比

合理
5 年均值 P/S
10.76
目前P/S
8.72
高估
14.14
低估
7.39

持有 KMTS 的大戶

J

Jaunty Global Limited

+ 持有KMTS

-1.42%

3個月報酬率

事件時間軸

2026-09-15 (ET)

09:00:00

Stock Futures Lower Ahead of Fed Policy Meeting

2026-09-14 (ET)

19:30:00

Anthropic CEO Warns of Out-of-Control AI, Tech Stocks Plunge

17:00:00

Kestra Medical Shares Down 7% to $22.32 After Q1 Earnings Miss

16:30:00

Kestra Reports Q1 Revenue of $30.97M, Exceeding Expectations

16:30:00

Kestra Raises FY27 Revenue Guidance to $141 Million

資訊

KMTS 常見問題 —— 由 Alphio AI 解答

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG. It operates in the Healthcare sector.

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易